Download PDF
Thromb Haemost 2007; 98(04): 710-712
DOI: 10.1160/TH07-09-0543
Editorial Focus
Schattauer GmbH

The onerous task of comparing treatments in inhibitor patients

Sam Schulman
1   Department of Medicine, McMaster University, Hamilton, Ontario, Canada and Coagulation Unit, Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
› Author Affiliations
Further Information

Publication History

Received 06 September 2007

Accepted 06 September 2007

Publication Date:
01 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Hedner U. Recombinant factor VIIa: its background, development and clinical use.. Curr Opin Hematol 2007; 14: 225-229.
    CrossrefPubMedGoogle Scholar
  • 2 Hedner U, Glazer S, Pingel K. et al. Successful use of recombinant factor VIIa in a patient with severe haemophilia A during synovectomy.. Lancet 1988; 2: 1193.
    PubMedGoogle Scholar
  • 3 Villar A, Aronis S, Morfini M. et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A.. Haemophilia 2004; 10: 352-359.
    CrossrefPubMedGoogle Scholar
  • 4 Shapiro AD, Gilchrist GS, Hoots WK. et al. Prospective, randomised trial of two doses of rFVIIa (Novo-Seven) in haemophilia patients with inhibitors undergoing surgery.. Thromb Haemost 1998; 80: 773-778.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Lusher JM, Roberts HR, Davignon G. et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group.. Haemophilia 1998; 4: 790-798.
    CrossrefPubMedGoogle Scholar
  • 6 Kavakli K, Makris M, Zulfikar B. et al. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial.. Thromb Haemost 2006; 95: 600-605.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Santagostino E, Mancuso ME, Rocino A. et al. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in haemophiliacs with inhibitors.. J Thromb Haemost 2006; 4: 367-371.
    CrossrefPubMedGoogle Scholar
  • 8 Schulman S, Bech Jensen M, Varon D. et al. Feasibility of using recombinant factor VIIa in continuous infusion.. Thromb Haemost 1996; 75: 432-436.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Bonde C, Jensen MB. Continuous infusion of recombinant activated factor VII: stability in infusion pump systems.. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 01) S103-105.
    PubMedGoogle Scholar
  • 10 Schulman S. the rFVIIa-CI group.. Safety, efficacy and lessons from continuous infusion with rFVIIa.. Haemophilia 1998; 4: 564-567.
    CrossrefPubMedGoogle Scholar
  • 11 Ludlam CA, Smith MP, Morfini M. et al. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation.. Br J Haematol 2003; 120: 808-813.
    CrossrefPubMedGoogle Scholar
  • 12 Smith MP, Ludlam CA, Collins PW. et al. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding.. Thromb Haemost 2001; 86: 949-953.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Mauser-Bunschoten EP, Koopman MM, Goede-Bolder AD. et al. Efficacy of recombinant factor VIIa administered by continuous infusion to haemophilia patients with inhibitors.. Haemophilia 2002; 8: 649-656.
    CrossrefPubMedGoogle Scholar
  • 14 Santagostino E, Morfini M, Rocino A. et al. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.. Thromb Haemost 2001; 86: 954-958.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Schulman S, d’Oiron R, Martinowitz U. et al. Experiences with continuous infusion of recombinant activated factor VII.. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 01) S97-S101.
    PubMedGoogle Scholar
  • 16 Pruthi RK, Mathew P, Valentino LA. et al. Hemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery: results from an open-label, randomized, multicenter trial.. Thromb Haemost 2007; 98: 726-732.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Mauser-Bunschoten EP, de Goede-Bolder A, Wielenga JJ. et al. Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and Belgium.. Neth J Med 1998; 53: 249-255.
    CrossrefPubMedGoogle Scholar